Solid-phase extraction combined with radioimmunoassay for measurement of zalcitabine (2',3'-dideoxycytidine) in plasma and serum.
Of the antiviral agents that are currently in clinical use in the US for therapy for human immunodeficiency virus infections, zalcitabine (ddC) is the most potent and is effective at the lowest plasma concentrations. The two reported procedures for measuring these low concentrations involve a chromatographic technique coupled with mass spectrometry. We have developed a procedure combining solid-phase extraction with a strong cation-exchange resin and commercially available RIA reagents for the quantification of ddC in plasma or serum. The method demonstrates good linearity, specificity, and precision, with overall CVs of < 10% from 2-20 micrograms/L and 17% at 0.8 microgram/L (the lower limit of quantitation). No significant cross-reactivity with nucleoside analogs other than ddC analogs was noted. The major advantages of this assay are its efficiency and relative simplicity, which should facilitate its performance in many laboratories.
Roberts
W L
WL
Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT 06510.
Buckley
T J
TJ
Rainey
P M
PM
Jatlow
P I
PI
D000998:Antiviral Agents / Q000097:blood*; D001682:Biological Availability; D006207:Half-Life; D006801:Humans; D008297:Male; D011786:Quality Control; D011863:Radioimmunoassay / Q000706:statistics & numerical data; D012680:Sensitivity and Specificity; D016047:Zalcitabine / Q000097:blood* / Q000493:pharmacokinetics; D015215:Zidovudine / Q000097:blood
D000998:Antiviral Agents; D015215:Zidovudine; D016047:Zalcitabine